New York, NY, United States of America

Natasha Levenkova

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Natasha Levenkova

Introduction: Natasha Levenkova is a distinguished inventor based in New York, NY. With a remarkable portfolio of two patents, she has made significant contributions to the field of biotechnology, particularly in the development of non-human animals with engineered genetic traits. Her work is poised to have a profound impact on antibody production and immunological research.

Latest Patents: Natasha's latest patents include:

1. **Non-human animals expressing exogenous terminal deoxynucleotidyltransferase**: This patent provides methods and compositions related to non-human animals that express exogenous Terminal Deoxynucleotidyltransferase (TdT).

2. **Non-human animals having an engineered immunoglobulin light chain locus**: This invention describes non-human animals (and/or non-human cells) with genomes comprising human antibody-encoding sequences. These animals express antibodies that include human Ig light chains, either in whole or in part, which are encoded by human Ig light chain sequences inserted into the animal's endogenous light chain locus. This patent also covers methods for producing antibodies from these engineered non-human animals.

Career Highlights: Natasha Levenkova is currently affiliated with Regeneron Pharmaceuticals, Inc., where she has been instrumental in advancing research in immunology and antibody engineering. Her innovative work has paved the way for new methodologies in therapeutic development and has furthered the understanding of genetic engineering applications in biomedical research.

Collaborations: Throughout her career, Natasha has collaborated with esteemed colleagues, including Lynn Macdonald and Andrew J. Murphy. These collaborations have fostered an environment of innovation and have contributed to the successful development of cutting-edge biotechnological advancements.

Conclusion: Natasha Levenkova is a prominent figure in the realm of biotechnological innovation. Her patents reflect her commitment to advancing medical science through the use of engineered non-human animals. With her continued contributions, she is well-positioned to lead future breakthroughs in antibody technology and genetic modification, further solidifying her legacy as a leading inventor in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…